is the Founder of NBT and will be responsible for the overall success of NBT and for making top-level managerial decisions. A world-renowned scientist (over 255 scientific publications and 1 patent and 5 pending patents) and an experienced administrator with 18+ years of executive management, Alexzander will be responsible for leading the development and execution of this initiative. As the CEO, Alexzander reports directly to, and is accountable to, the Board of Directors for the performance of NBT.
is a Founding member of NBT and is the current Deputy Managing Director/Head of Strategy of the National Social Security Fund (NSSF) in Uganda. Patrick is a highly successful accountant and business administrator. Patrick was awarded Bachelor of Science degree from Liberty University in Lynchburg, Virginia and an MBA from the University of South Carolina, at Columbia. He is also a Certified Public Accountant, and a member of the Institute of Certified Public Accountants of Uganda. As CFO, Patrick has primary responsibility for managing the NBT's finances, including financial planning, management of financial risks, record-keeping, and financial reporting.
is a Founding member of NBT and will be responsible for translating and implementing the overall product vision and go-to-market strategy of NBT’s full product and service portfolio. Hossein has been instrumental in building innovative solutions that not only solve substantial client based existing challenges, but address opportunities driven by the monumental shifts occurring in pharmaceutical drug manufacturing, and the development and implementation of an agile product prioritization and development process that appropriately balances innovation, speed, quality and scale.
To ensure the success of NBT and maintain a high international ranking as a safe and effective pharmaceutical manufacturing company, NBT has established a Scientific Advisory Board. This advisory board is composed of eminent successful academic and business executives and experts in biotechnology and the pharmaceutical industry.
is currently the Director for Molecular and Cellular Radiation Oncology at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. Dr Calderwood is world renown for his research on the design of molecular chaperone-based vaccines and on the development of compounds targeting breast cancer. Prof Calderwood is also the Founder & CEO of Chaperonix, a biopharmaceutical company focused on molecular chaperone research.
Is the Co-Leader, Gastrointestinal Cancer Program, Mayo Clinic Cancer Center, Endowed Chair, Florida Department of Health, Radiation Oncology, Mayo Clinic, and Chair, Scientific Program and Education Committees, ASTRO Academy. Dr Krishnan specializes in the radiotherapy treatment of gastrointestinal cancers. Research in Dr. Krishnan's Nanotechnology and Radiation Biology Laboratory includes strategies to sensitize tumors to radiation therapy using nanoparticles, chemotherapy, botanicals, immunotherapy and novel radiation techniques including particle therapy, mini beams and boron neutron capture therapy. He evaluates approaches to protect normal tissues from radiation injury using novel agents. Dr. Krishnan also studies patterns of gene expression and imaging characteristics in human tumors that predict response to radiotherapy and chemotherapy. His research has been funded by the National Institutes of Health for over a decade. Dr. Krishnan’s focus areas include; Nanotechnology, Drug-radiation interactions, High-linear energy transfer (LET) treatments, Novel therapeutic modalities and Predictors of radiotherapy outcome.
is currently Professor at the Technical University Munich, and Director of the Celleurope Project, and leads the Department of Experimental Radiooncology and Radiobiology and is also the leader of the Clinical Cooperation Group (CCG) at the Technical University, Munich, Germany. Prof. Multhoff is also a Commissioner of the German Academic Exchange Service (DAAD) in the EU. Dr Multhoff is also the Founder and CEO of Multimmune GmbH, a biopharmaceutical company focused on the development of innovative therapeutic approaches for the treatment of cancers that express heat shock proteins.
NBT Board of Directors consists of prominent individuals with solid character traits and personal integrity.
is a Founding member of NBT and currently the Director of the Uganda Cancer Institute (UCI) and Senior Consultant Oncologist at Mulago Hospital in Kampala, Uganda. UCI is a public, specialized, tertiary care medical facility owned by the Uganda Ministry of Health and the only dedicated cancer treatment facility in a country of 42.9 million people. Jackson studied oncology at Case Western Reserve University before returning to Uganda to head this government-owned cancer institute in 2004. As Director of the UCI, Jackson has extensive experience working closely with national and international government and non-governmental organization to improve healthcare of patients in Uganda and the entire Great Lakes Region. Jackson’s clinical oncology background and daily interaction with cancer patients makes his perspective on the lack of affordable cancer medicines extremely important to NBT.
Ed is a founding member of NBT and currently President of Nuetron.ai which specializes in helping customers develop scalable AI platforms that solve critical business scaling challenges. Prior to starting Neutron, Ed was Chief Data Officer at Intel responsible for platform innovation in leading edge silicon integration. Ed brings more than 20+ years of management and manufacturing engineering expertise in multiple generations of high-tech process technology transfers, operations standardization, intellectual property management, and product ramp and yield best practices. Ed has a MSc in Chemical Engineering from Auburn University and an MBA from Thunderbird School of Global Management. He is a proven business leader who has led large technical teams to deliver multiple generations of silicon technologies that have generated billions in sales from cloud computing and mobile products. Ed also brings a strong record of building highly engaged organizations that deliver outstanding business results in the high-technology manufacturing industry.
Vertical Startups (VS) to date across strategy, talent development, information technology, strategic partnerships, innovation, and the move into advanced analytics to drive significant business value for Intel. My team and I created a unique blue print for Intel's business (one that is confidential and not shared here), but also a model that is clearly applicable across any business to leverage analytics as a key capability to win.
Ed is a Data Scientist and a business results-driven professional with extensive experience in product platform development strategy, development, execution, and operational scaling. He has led multiple initiatives that span across design-led innovation, design thinking, design ethnography, and interaction design. He has worked with various consumer based products that leverage AI and ML platforms including self-driving vehicles and industrial robotics. Prior to Intel, Ed worked with Philips Electronics where he led various multi-billion dollar IC product development and deployment projects in the wireless consumer electronics business sector.
Ed has an MBA from Thunderbird School of Global Business and Chemical Engineering and Device Physics From Auburn University in Alabama.
